Immunome, Inc.
NASDAQ:IMNMBiotechnology
-$0.42 today
- Market cap
- $1.98B
- Beta
- 2.07
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$1.99
Volume 1.41M
Average 1.23M
IMNM Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Immunome, Inc.NASDAQ: IMNM
Free Cash Flow · Q3 FY2026 · quarter ended Sep 2026
Free cash flow growth accelerates
Q3 FY2026 free cash flow of $61.24M (cash outflow) rose 47.1% year over year, ahead of the +24.3% change in trailing-twelve-month free cash flow. Sequentially, it fell 4.1% from the prior quarter. Over 3 fiscal years it compounded at +90.7% a year.
Context
- Free cash flow amounted to 2890.1% of revenue in FY2025, up 1072.8 pp from a year earlier.
- Free cash flow grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +47.1% holds above the trailing-twelve-month pace of +24.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (200.6M) USD
- Year-over-year change
- -22.1%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (200.6M) | -22.1% |
| FY2024 | 2024-12-31 | (164.3M) | -1856.2% |
| FY2023 | 2023-12-31 | (8.4M) | +71.0% |
| FY2022 | 2022-12-31 | (28.94M) | -58.1% |
| FY2021 | 2021-12-31 | (18.31M) | — |
Free Cash Flow vs competitors
How IMNM compares with its peers on the latest reported figures
- Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +24.3% is the 4th highest of 11, against a peer median of +11.6%.
- Over three fiscal years its annual growth of +90.7% compares with a peer median of +26.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $259.45M USD | +42.8% | +26.5% | 231652.7% | |
| LTM Sep 2026 | $238.7M USD | +24.3% | +90.7% | — | |
| LTM Mar 2026 | $229.01M USD | +25.5% | +34.0% | 360.7% | |
| LTM Mar 2026 | €188.49M EUR | +10.8% | — | 505.4% | |
| LTM Mar 2026 | $152.14M USD | -23.4% | +246.3% | 152.7% | |
| LTM Mar 2026 | $134.47M USD | +12.4% | +54.4% | — | |
| LTM Mar 2026 | $71.69M USD | -1.0% | -2.9% | 45.6% | |
| LTM Mar 2026 | $35.14M USD | +23.0% | +6.5% | — | |
| LTM Mar 2026 | $32.77M USD | +144.6% | +49.3% | — | |
| LTM Mar 2026 | $30.72M USD | -217.9% | -39.8% | 8.0% | |
| LTM Sep 2026 | $27.3M USD | -10.9% | +0.1% | — | |
| Peer median (excluding IMNM) | — | +11.6% | +26.5% | 256.7% | |
Competitors are the stored peer set for IMNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (24.71M) | (36.9M) | (106.81M) | (292.96M) | (212.39M) |
| Depreciation & Amortization | 755K | 631K | 728K | 2.1M | 2.96M |
| Deferred Income Tax | (500K) | (7.27M) | 0 | 0 | 0 |
| Stock-Based Compensation | 3.45M | 5.33M | 6.22M | 15.75M | 25.69M |
| Change in Working Capital | 2.78M | 2.24M | 12M | 14.87M | (15.23M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.78M | (677K) | (608K) | 9.53M | (9.16M) |
| Other Working Capital | 998K | 2.92M | 12.61M | 5.35M | (6.06M) |
| Other Non-Cash Items | 4K | 7.27M | 80.29M | 149.45M | 8.06M |
| Operating Cash Flow | (18.23M) | (28.69M) | (7.57M) | (110.79M) | (190.92M) |
| Capital Expenditures | (79K) | (248K) | (831K) | (53.51M) | (9.69M) |
| Acquisitions (Net) | 0 | 0 | 9.28M | 0 | 0 |
| Purchases of Investments | 0 | 0 | (38.93M) | (186.56M) | (123.27M) |
| Sales of Investments | 0 | 0 | 0 | 155M | 200M |
| Other Investing Activities | 0 | 0 | 0 | (46.34M) | (6.25M) |
| Investing Cash Flow | (79K) | (248K) | (30.48M) | (85.06M) | 60.8M |
| Debt Repayment | (113K) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 27.23M | 32K | 34K | 250M | 640.36M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 656K | 0 | 116.37M | (9.47M) | 0 |
| Financing Cash Flow | 27.77M | 32K | 116.41M | 240.53M | 640.36M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 9.46M | (28.91M) | 78.36M | 44.67M | 510.24M |
| Free Cash Flow | (18.31M) | (28.94M) | (8.4M) | (164.3M) | (200.6M) |
Immunome, Inc.
NASDAQ:IMNM
Intrinsic Alpha fair value
Locked
Current Price
$16.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.